Arizona Tribune - Laser Photonics Secures $1.05 Million Order from U.S. Pharmaceutical Manufacturer for High-Speed Tablet Drilling System

The TD-70 drills the precision orifices that regulate how controlled-release medications are delivered to patients, an application where a fraction of a millimeter can determine therapeutic performance. Two capabilities drove the customer's selection: throughput of up to 70,000 tablets per hour, and a dual-camera vision system that inspects every tablet twice, automatically rejecting any unit outside specification before it moves downstream. Detailed technical specifications for the platform are available on the CMS Laser website.

Notably, the order covers a complete production line rather than a single machine. Alongside the drilling system, CMS Laser is supplying the tablet handling tooling and conveyor transport that integrate the platform into the customer's production flow, together with the full IQ, OQ, and PQ validation package and on-site installation by its own engineers. That is the documentation and support a pharmaceutical manufacturer needs to qualify new equipment under its GMP quality system, and providing it as part of the order positions CMS Laser inside the customer's qualification process as a technical partner rather than solely an equipment vendor. The Company believes a successful deployment has the potential to support additional system orders as the relationship develops. The system will be built at CMS Laser's manufacturing facility in Winter Park, Florida.

The order follows the Company's expansion into precision medical device manufacturing announced in May 2026, reflecting continued commercial traction for CMS Laser's precision drilling platforms across regulated, high-value healthcare end markets.

In addition to this order, Laser Photonics intends to expand its investment in CMS Laser and its technology platform as part of a broader strategy to support the subsidiary's growth and continued product development. The Company views precision laser drilling as a core capability within its portfolio and intends to direct additional resources toward CMS Laser's engineering, product development, and production capabilities in support of demand across pharmaceutical, medical device, and other regulated end markets.

Management Commentary

"This order reflects the strength of CMS Laser's position in pharmaceutical manufacturing and our ability to win new customers on the basis of engineering capability and process quality," said Ann Tewari, Interim President of Laser Photonics. "Laser drilling for controlled-release tablets is an application where there is very little tolerance for variability, because the orifice we create determines how the medication is delivered to the patient. Our customer evaluated the TD-70 against that standard and selected it for a production-scale deployment, which we view as a meaningful validation of the platform. Just as important, we are delivering the tooling, the transport and the full validation package alongside the system, so the customer receives a production line they can qualify and run. Establishing that capability inside a new customer's operations at production scale is exactly the kind of foothold we look to build on."

For more information about Laser Photonics' portfolio of industrial and defense laser systems, please visit laserphotonics.com.

About Laser Photonics Corporation

Laser Photonics Corporation (NASDAQ:LASE) is a global leader in laser systems for industrial and defense applications. The Company develops and manufactures advanced laser technologies used in cleaning, surface preparation, and precision material processing across demanding operating environments. Laser Photonics serves a broad range of end markets, including defense and government, aerospace, energy, maritime, automotive, and advanced manufacturing. Through a combination of internal development, strategic acquisitions, and partnerships, the Company continues to expand its product portfolio and address new applications where performance, efficiency, and environmental considerations are critical. For more information, please visit laserphotonics.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations as of the date of this press release and involve risks and uncertainties that may cause results to differ materially from those indicated by these forward-looking statements. These forward-looking statements include, among other things, statements regarding the anticipated performance and benefits of the TD-70 tablet drilling system, the timing and success of the system's manufacture, installation, validation and deployment into the customer's future production, the potential for additional system orders from this customer, broader adoption of CMS Laser's pharmaceutical laser drilling technology, and the Company's ability to expand its presence within the pharmaceutical and other regulated end markets. These risks and uncertainties include, but are not limited to, the impacts of federal government funding disruptions and shutdowns on our contracts, operations, capital-raising activities, and strategic initiatives. We encourage readers to review the "Risk Factors" in our Registration Statement and other filings with the Securities and Exchange Commission for a comprehensive understanding. Laser Photonics Corp. undertakes no obligation to revise or update any forward-looking statements, except as required by applicable laws or regulations, to reflect events or circumstances after the date of this press release.

Investor Relations Contact
Lucas A. Zimmerman & Ian Scargill
MZ Group - MZ North America
(262) 357-2918
[email protected]
www.mzgroup.us

SOURCE: Laser Photonics Corp.

View the original press release on ACCESS Newswire

O.Brown--AT